GenSight Biologics S.A. (SIGHT.PA)
EUR 0.29
(-3.52%)
EUR 0.29
(-3.52%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -26.22 Million EUR | 5.08% |
| 2022 | -27.62 Million EUR | 3.47% |
| 2021 | -28.61 Million EUR | 15.87% |
| 2020 | -34.01 Million EUR | -10.77% |
| 2019 | -30.71 Million EUR | 8.2% |
| 2018 | -33.45 Million EUR | -38.74% |
| 2017 | -24.11 Million EUR | -9.19% |
| 2016 | -22.08 Million EUR | -61.73% |
| 2015 | -13.65 Million EUR | -104.67% |
| 2014 | -6.67 Million EUR | -141.46% |
| 2013 | -2.76 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -2.92 Million EUR | 58.98% |
| 2024 Q2 | -2.92 Million EUR | 0.0% |
| 2023 Q3 | -7.12 Million EUR | 40.4% |
| 2023 Q1 | -5.98 Million EUR | 29.26% |
| 2023 Q4 | -7.12 Million EUR | 0.0% |
| 2023 FY | -26.22 Million EUR | 5.08% |
| 2023 Q2 | -11.96 Million EUR | -100.0% |
| 2022 Q4 | -8.45 Million EUR | 0.0% |
| 2022 Q3 | -8.45 Million EUR | 21.08% |
| 2022 Q1 | -5.35 Million EUR | 47.26% |
| 2022 Q2 | -10.71 Million EUR | -100.0% |
| 2022 FY | -27.62 Million EUR | 3.47% |
| 2021 FY | -28.61 Million EUR | 15.87% |
| 2021 Q2 | -8.3 Million EUR | -100.0% |
| 2021 Q4 | -10.15 Million EUR | 0.0% |
| 2021 Q1 | -4.15 Million EUR | 79.17% |
| 2021 Q3 | -10.15 Million EUR | -22.31% |
| 2020 Q2 | -14.07 Million EUR | -91.62% |
| 2020 Q3 | -9.66 Million EUR | 31.38% |
| 2020 Q4 | -19.93 Million EUR | -106.38% |
| 2020 FY | -34.01 Million EUR | -10.77% |
| 2020 Q1 | -7.34 Million EUR | 45.03% |
| 2019 Q3 | -6.76 Million EUR | 61.01% |
| 2019 Q2 | -17.34 Million EUR | -100.0% |
| 2019 Q1 | -8.67 Million EUR | 60.21% |
| 2019 FY | -30.71 Million EUR | 8.2% |
| 2019 Q4 | -13.36 Million EUR | -97.66% |
| 2018 Q1 | -5.82 Million EUR | 16.72% |
| 2018 Q3 | -10.89 Million EUR | 6.52% |
| 2018 Q4 | -21.79 Million EUR | -100.0% |
| 2018 FY | -33.45 Million EUR | -38.74% |
| 2018 Q2 | -11.65 Million EUR | -100.0% |
| 2017 Q4 | -6.99 Million EUR | 0.0% |
| 2017 Q1 | -5.05 Million EUR | 20.78% |
| 2017 FY | -24.11 Million EUR | -9.19% |
| 2017 Q2 | -5.05 Million EUR | 0.0% |
| 2017 Q3 | -6.99 Million EUR | -38.43% |
| 2016 Q1 | -4.65 Million EUR | -3.29% |
| 2016 Q3 | -6.38 Million EUR | -37.03% |
| 2016 Q2 | -4.65 Million EUR | 0.0% |
| 2016 Q4 | -6.38 Million EUR | 0.0% |
| 2016 FY | -22.08 Million EUR | -61.73% |
| 2015 Q3 | -4.5 Million EUR | -94.63% |
| 2015 Q4 | -4.5 Million EUR | -0.0% |
| 2015 FY | -13.65 Million EUR | -104.67% |
| 2015 Q2 | -2.31 Million EUR | 0.0% |
| 2015 Q1 | -2.31 Million EUR | -9.25% |
| 2014 Q4 | -2.12 Million EUR | 0.0% |
| 2014 FY | -6.67 Million EUR | -141.46% |
| 2014 Q1 | -1.21 Million EUR | 0.0% |
| 2014 Q3 | -2.12 Million EUR | -74.61% |
| 2014 Q2 | -1.21 Million EUR | 0.0% |
| 2013 FY | -2.76 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -645.31% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 82.253% |
| Adocia SA | -21.16 Million EUR | -23.901% |
| Aelis Farma SA | -5.07 Million EUR | -416.345% |
| Biophytis S.A. | -17.02 Million EUR | -54.0% |
| Advicenne S.A. | -7.03 Million EUR | -272.92% |
| genOway Société anonyme | 1.56 Million EUR | 1772.647% |
| IntegraGen SA | -171.39 Thousand EUR | -15197.639% |
| Medesis Pharma S.A. | -3.95 Million EUR | -562.206% |
| Neovacs S.A. | -8.74 Million EUR | -199.882% |
| NFL Biosciences SA | -3.74 Million EUR | -600.045% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 33219.024% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -726.882% |
| Sensorion SA | -22.06 Million EUR | -18.839% |
| Theranexus Société Anonyme | -6.82 Million EUR | -284.01% |
| TME Pharma N.V. | -6.73 Million EUR | -289.252% |
| Valbiotis SA | -7.36 Million EUR | -255.863% |
| TheraVet SA | -1.57 Million EUR | -1569.312% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -28.883% |
| argenx SE | -272.91 Million EUR | 90.393% |
| BioSenic S.A. | -28.77 Million EUR | 8.889% |
| Celyad Oncology SA | -8.44 Million EUR | -210.369% |
| DBV Technologies S.A. | -67.26 Million EUR | 61.022% |
| Galapagos NV | 211.69 Million EUR | 112.386% |
| Genfit S.A. | -28.89 Million EUR | 9.255% |
| GeNeuro SA | -14.75 Million EUR | -77.678% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -70.481% |
| Innate Pharma S.A. | -7.57 Million EUR | -246.367% |
| Inventiva S.A. | -110.42 Million EUR | 76.256% |
| MaaT Pharma SA | -19.71 Million EUR | -32.982% |
| MedinCell S.A. | -25.03 Million EUR | -4.721% |
| Nanobiotix S.A. | -39.7 Million EUR | 33.955% |
| Onward Medical N.V. | -36.18 Million EUR | 27.531% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -682.0% |
| OSE Immunotherapeutics SA | -23 Million EUR | -13.985% |
| Oxurion NV | -18.96 Million EUR | -38.226% |
| Pharming Group N.V. | -9.75 Million EUR | -168.741% |
| Poxel S.A. | -35.09 Million EUR | 25.278% |
| Transgene SA | -22.32 Million EUR | -17.431% |
| Financière de Tubize SA | 88.15 Million EUR | 129.744% |
| UCB SA | 343 Million EUR | 107.644% |
| Valneva SE | -101.42 Million EUR | 74.149% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 7.487% |